Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
...
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
- Associated Therapies
- -
Sex differences of fall-risk-increasing drugs in the middle-aged and elderly
101,746 AE reports analyzed, 68,492 (67.3%) female, 32,547 (32.0%) male; average age 69.8 ± 11.5 (female), 71.5 ± 11.2 (male). Report numbers fluctuated since 2004, peaking 2010-2012 and 2018-2019. Most reports from America (62.3% female, 55.4% male), mainly hospitalization (51.3% female, 51.2% male). Multiple sclerosis most reported AE (14.2% female, 6.2% male). Signals detected using ROR and BCPNN algorithms; top signals varied by sex. Sex differences in signal numbers noted in 2nd-level ATC classes. F/M ratio analysis on shared signals showed 33 positive for females, 38 for males, 48 no difference. Specific drugs showed stronger associations with falls in one sex over the other across various ATC classifications.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath